Maxim Group: VolitionRx (OTC:VNRX) has $6 Target Has New Rating.

May 17, 2018 - By Julie Barnes

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 5.80, from 2017Q3’s 7. The ratio turned negative due to VolitionRx Limited positioning: 3 sold and 2 reduced. 2 funds bought holdings and 4 increased holdings. Investors holded 9.30 million in 2017Q3 but now own 4.52 million shares or 51.36% less.

Royal Bancshares Of Canada owns 14,007 shs. National Bank & Trust Of Mellon has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Creative Planning, a Kansas-based fund reported 13,200 shs. Knoll Cap L P invested 0.91% in VolitionRx Limited (NYSEAMERICAN:VNRX). Garrison Bradford & holds 0.04% or 15,500 shs in its capital. Blackrock holds 0% or 11,219 shs. Leisure Management holds 74,863 shs. Bessemer has 10,000 shs. Lagoda Mngmt Lp has 3.52 million shs for 3.94% of their capital. Geode Limited Liability reported 0% stake. Morgan Stanley has 63,400 shs. Northern Tru reported 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Vanguard Grp Inc accumulated 0% or 204,994 shs. Brown Brothers Harriman And holds 0% or 3,823 shs in its capital. Bridgeway Capital Management invested 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX).

What Price Target Has Maxim Group Given VolitionRx (OTC:VNRX)

On Wednesday, 16 May, a coverage started with VolitionRx (OTC:VNRX) that has “Buy” rating and $6 target price per share on VNRX. That’s upside potential of 166.67 % from firm’s last stock close price.

Ticker’s shares touched $2.25 during the last trading session after 8.70% change.VolitionRx Limited has 145,762 shares volume, 3.92% up from normal. VNRX is downtrending and has moved 42.82% since May 17, 2017. VNRX underperformed by 54.37% the S&P500.

On August, 8 VolitionRx Limited (NYSEAMERICAN:VNRX)’s earnings report is expected by WallStreet, as reported by RTT. Last year’s earnings per share was $-0.13, while now analysts expect change of 30.77 % down from current $-0.17 earnings per share. After $-0.17 earnings per share was announced previous quarter, analysts now see EPS growth of 0.00 % for VolitionRx Limited.

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide.The firm is valued at $67.57 million. The firm develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Currently it has negative earnings.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: